IPATF Stock Soars: Subsidiary Receives Exclusive License from Stanford

IPATF stock

On Friday, April 26, ImmunoPrecise Antibodies’ subsidiary U-Protein Express disclosed that it’s obtained an exclusive license from Stanford University. The license allows U-Protein Express to manufacture and sell Wnt surrogate Fc. On the news, IPATF stock soared, up nearly 15% at the time of writing on the OTC market.

Here’s what we know.

U-Protein Express Obtains License from Stanford, IPATF Stock Soars 

U-Protein Express is a wholly-owned subsidiary of ImmunoPrecise Antibodies (TSXV:IPA) (OTCQB:IPATF), which is a therapeutic antibody discovery company based in Victoria, British Columbia, Canada. Today, the subsidiary said Stanford University has granted it an exclusive license to manufacture and sell Wnt surrogate FC. For those who don’t know, Wnt surrogate FC is a novel protein and substitute for the Wnt protein.

Receiving an exclusive license from Stanford University is significant as is. After all, it’s one of the top universities in the world. But there are other reasons the market is reacting the way it is, sending IPATF stock into the double-digits.

Enter Your E-mail Address To Subscribe

* indicates required
 

>> Penny Stocks to Watch: Limelight Network Stock and DHX Media

First, the nature of the license makes sure ImmunoPrecise Antibodies is the only manufacturer and supplier of the novel protein to the marketplace. Second, there’s a high demand for Wnt surrogate FC right now as it can help grow organoids. So, being the single global supplier of the protein, it’s likely the Canadian company will be on a lot of people’s radar.

IPATF Stock and IPA Stock 

As mentioned, IPATF stock jumped on the news of U-Protein Express obtaining an exclusive license from Stanford. As of 2:32 PM EDT, according to Yahoo Finance, IPATF stock is trading at $0.5950, which puts it up 12.54% on the OTC market. Earlier in the trading day, IPATF stock was up around 14%.

On the TSXV, as of 1:49 PM EDT, IPA stock is up 6.67%, trading at $0.80.

Takeaway

What do you think of the news? With ImmunoPrecise Antibodies being the single manufacturer of Wnt surrogate FC, good things are sure to come to IPATF and IPA stock.

Let us know in the comments below.

>> Read More Biotech News

Please See Disclaimer

Featured image: DepositPhotos © VitalikRadko


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, ImmunoPrecise Antibodies Ltd. Market Jar Media Inc. has or expects to receive the following amounts from Native Ads Inc. in the amount of one hundred nine thousand American dollars for 21 campaign days (14 business days) for digital marketing.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on Market Jar Media Inc. should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Market Jar Media Inc.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.